Clinical Trial Detail

NCT ID NCT04112498
Title A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

urinary bladder cancer

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

melanoma

gastric adenocarcinoma

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma

Therapies

Nivolumab + Relatlimab + rHuPH20

Age Groups: adult senior

No variant requirements are available.